Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 196

Sort by

Sort Order Select

Journal Articles

Venetian: A Phase 2b/3 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) and Optimize Initiation of Venetoclax (Ven) in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

William G. Wierda, Matthew S. Davids, Jeff P. Sharman, Nilanjan Ghosh, Yang Feng, Mary Jean Fusco, Jacqueline Hilger-Rolfe, Chen Qian, Wendy J. Sinai, Sophie Wimberley, John F. Seymour

Blood (2024) 144 (Supplement 1): 6784.

https://doi.org/10.1182/blood-2024-207716

Published: 2024

Journal Articles

Comparative Assessment of Cell Line Models for Optimal Representation of Chronic Lymphocytic Leukemia

Salem Elias, Jeremy Zhang, Ritu Somayaji, Stephanie Chamberlain, Stephen Jun Fei Chong, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 6759.

https://doi.org/10.1182/blood-2024-203777

Published: 2024

Journal Articles

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2024) 144 (Supplement 1): 1865.

https://doi.org/10.1182/blood-2024-206556

Published: 2024

Journal Articles

Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy

Daniel Sungchul Choi, Yue Ren, Svitlana Tyekucheva, Stacey M. Fernandes, Mariia Mikhaleva, Kiyomi Mashima, Rayan Fardoun, Samantha J. Shupe, Stephen Martindale, Matthew S. Davids, Jennifer R. Brown, Inhye E. Ahn

Blood (2024) 144 (Supplement 1): 587.

https://doi.org/10.1182/blood-2024-208951

Published: 2024

Journal Articles

Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

Blood (2024) 144 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2024-203414

Published: 2024

Journal Articles

Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy

Roberta Santos Azevedo, Mariia Mikhaleva, Kiyomi Mashima, Stephen Martindale, Stacey M. Fernandes, Svitlana Tyekucheva, Inhye E. Ahn, Matthew S. Davids, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 583.

https://doi.org/10.1182/blood-2024-206576

Published: 2024

Journal Articles

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Blood (2024) 144 (Supplement 1): 2786.

https://doi.org/10.1182/blood-2024-208159

Published: 2024

Journal Articles

Pharmacodynamic Analysis of Mcl-1 and RNA Pol II Ser2 Phosphorylation in Blasts from Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated on a Phase 1 Study of Venetoclax Plus Voruciclib

Nathalie Javidi-Sharifi, Jeremy Zhang, Sandra Wiley, Richard G Ghalie, Alexey V. Danilov, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 4147.

https://doi.org/10.1182/blood-2024-203689

Published: 2024

Journal Articles

Systems-Based Care Improvements to Optimize BTK Inhibitors in Chronic Lymphocytic Leukemia Vary in the Community Setting

Tariqa Ackbarali, Danielle M. Brander, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 3662.

https://doi.org/10.1182/blood-2024-212306

Published: 2024

Journal Articles

Mechanistic Insights and Therapeutic Potential of a PRMT5 Inhibitor Combined with Venetoclax in B Cell Malignancies

Fen Zhu, Jing Wang, Christine E. Ryan, Liam Hackett, Jeremy Zhang, Stephen Jun Fei Chong, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 1615.

https://doi.org/10.1182/blood-2024-205802

Published: 2024

Journal Articles

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Inhye E. Ahn, Yue Ren, David C. Fisher, Austin I. Kim, Nancy E. Kaddis, Jon E. Arnason, John P. Winters, III, Sobana Balasubramanian, Heather A. Walker, Victoria Patterson, Stacey M. Fernandes, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2024-201668

Published: 2024

Journal Articles

Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies

Kadriye Nehir Cosgun, Mark E Robinson, Nikol Agadzhanian, Philipp Berning, David Fonseca-Arce, Etienne Leveille, Shalin Kothari, Matthew S. Davids, Julia Jellusova, Markus Müschen

Blood (2024) 144 (Supplement 1): 1412.

https://doi.org/10.1182/blood-2024-208598

Published: 2024

Journal Articles

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Yesid Alvarado-Valero, Rachel J. Cook, Shira N. Dinner, Michael Keng, Kebede Begna, Sameem Abedin, MHD Monzr M. Al Malki, Vijaya Raj Bhatt, Nathalie Javidi-Sharifi, Prabhu Rajagopolan, Sandra Wiley, Richard G Ghalie, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 2878.

https://doi.org/10.1182/blood-2024-198718

Published: 2024

Journal Articles

Final Update of Safety, Efficacy and T-Cell Predictive Biomarkers from a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Geoffrey Shouse, Leslie Popplewell, Alex Muir, Tanya Siddiqi, Jasmine Zain, Alex F. Herrera, Olga Danilova, Stephen E Spurgeon, Lili Wang, Adam S Kittai, Lu Chen, Matthew S. Davids, Alexey V. Danilov

Blood (2024) 144 (Supplement 1): 4484.

https://doi.org/10.1182/blood-2024-209610

Published: 2024

Journal Articles

Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

Blood (2024) 144 (Supplement 1): 5099.

https://doi.org/10.1182/blood-2024-198742

Published: 2024

Journal Articles

Orally Bioavailable CDK9 Inhibitor Voruciclib Downregulates Oncogenic Pathways in Leukemic Cells from Patients Treated on a Clinical Trial

Edward C. Dominguez, Carly Roleder, Canping Chen, Zheng Xia, Sandra Wiley, Matthew S. Davids, Alexey Danilov

Blood (2024) 144 (Supplement 1): 721.

https://doi.org/10.1182/blood-2024-198693

Published: 2024

Journal Articles

Salinomycin Nanoparticles Induce Ferroptosis and Synergize with the BCL-2 Inhibitor Venetoclax to Promote AML Cell Death

Suiyang Liu, Wei Ni, Fen Zhu, Basudev Chowdhury, Ilene A. Galinsky, Matthew S. Davids, Ellen L Weisberg, Surender Kharbanda, Richard M. Stone

Blood (2024) 144 (Supplement 1): 5820.

https://doi.org/10.1182/blood-2024-203992

Published: 2024

Journal Articles

Clonal Evolution during Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients

Saurabh Yadav, Sumbul Jawed Khan, Binu Kandathilparambil Sasi, Elizabeth F. Cohen, Kiyomi Mashima, Hannah Cormier, Stacey M. Fernandes, Samantha J. Shupe, Roberta Santos Azevedo, Mariia Mikhaleva, Philippe Armand, David C. Fisher, Matthew S. Davids, Inhye E. Ahn, Michael Y. Tolstorukov, Mark A. Murakami, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 4611.

https://doi.org/10.1182/blood-2024-207527

Published: 2024

Journal Articles

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Blood (2024) 144 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2024-199577

Published: 2024

Journal Articles

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Blood (2024) 144 (Supplement 1): 4614.

https://doi.org/10.1182/blood-2024-207408

Published: 2024

NARROW

Venetian: A Phase 2b/3 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) and Optimize Initiation of Venetoclax (Ven) in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Comparative Assessment of Cell Line Models for Optimal Representation of Chronic Lymphocytic Leukemia

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy

Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Pharmacodynamic Analysis of Mcl-1 and RNA Pol II Ser2 Phosphorylation in Blasts from Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated on a Phase 1 Study of Venetoclax Plus Voruciclib

Systems-Based Care Improvements to Optimize BTK Inhibitors in Chronic Lymphocytic Leukemia Vary in the Community Setting

Mechanistic Insights and Therapeutic Potential of a PRMT5 Inhibitor Combined with Venetoclax in B Cell Malignancies

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Final Update of Safety, Efficacy and T-Cell Predictive Biomarkers from a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

Orally Bioavailable CDK9 Inhibitor Voruciclib Downregulates Oncogenic Pathways in Leukemic Cells from Patients Treated on a Clinical Trial

Salinomycin Nanoparticles Induce Ferroptosis and Synergize with the BCL-2 Inhibitor Venetoclax to Promote AML Cell Death

Clonal Evolution during Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only